Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This Phase III trial tests whether adding the experimental drug TQB3616 to standard hormone therapy can help prevent breast cancer from returning in women with HR-positive, HER2-negative breast cancer after surgery. About 1,946 women will receive either TQB3616 or a placebo, plus…

This phase 2 study tests a new drug (TQB3616) combined with hormone therapy for people with a common type of breast cancer (HR-positive, HER2-negative) that has returned or spread and no longer responds to a standard class of drugs called CDK4/6 inhibitors. The trial enrolls 33 a…

This study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and nei…

This Phase 3 trial tests whether adding anlotinib (a daily pill) to standard chemotherapy can help people with a certain type of advanced colorectal cancer live longer without the disease getting worse. About 748 participants with RAS/BRAF wild-type cancer that has spread will re…

This phase 3 trial tests whether adding an experimental drug (TQB3616) to standard hormone therapy (fulvestrant) can delay cancer growth in people with HR-positive, HER2-negative advanced breast cancer. About 432 participants will receive either the combination or a placebo plus …

This study tests a new tablet called TQ05105 in 45 adults with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. The drug works by blocking a protein pathway involved in inflammation. The goal is to find the right dose and see if it c…

This Phase 2 trial tests whether adding TQ-A3334 tablets to standard nucleoside analog drugs can better control chronic hepatitis B. About 116 adults with the infection will receive either the combination or a placebo plus standard drugs. The main goal is to see if the combinatio…

This study evaluates whether a single dose of TQ05105, a JAK inhibitor being developed for myelofibrosis, affects the heart's electrical activity (QT interval) in healthy Chinese adults. Sixty participants receive TQ05105, placebo, and moxifloxacin (a positive control) in a cross…

This early-stage study in 16 healthy adults checks if taking a common stomach acid drug (rabeprazole) changes how the body absorbs a new experimental drug (TQ05105) being developed for myelofibrosis. Participants take TQ05105 alone and later with rabeprazole to compare drug level…